ATE138196T1 - Testverfahren für und behandlung von autoimmunkrankheiten - Google Patents

Testverfahren für und behandlung von autoimmunkrankheiten

Info

Publication number
ATE138196T1
ATE138196T1 AT90906028T AT90906028T ATE138196T1 AT E138196 T1 ATE138196 T1 AT E138196T1 AT 90906028 T AT90906028 T AT 90906028T AT 90906028 T AT90906028 T AT 90906028T AT E138196 T1 ATE138196 T1 AT E138196T1
Authority
AT
Austria
Prior art keywords
treatment
autoimmune diseases
testing
diseases
diagnosis
Prior art date
Application number
AT90906028T
Other languages
English (en)
Inventor
Michael Daniel Cahalan
Kanianthara George Chandy
Stephen Grissmer
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE138196T1 publication Critical patent/ATE138196T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90906028T 1989-03-06 1990-03-05 Testverfahren für und behandlung von autoimmunkrankheiten ATE138196T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31949989A 1989-03-06 1989-03-06

Publications (1)

Publication Number Publication Date
ATE138196T1 true ATE138196T1 (de) 1996-06-15

Family

ID=23242496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90906028T ATE138196T1 (de) 1989-03-06 1990-03-05 Testverfahren für und behandlung von autoimmunkrankheiten

Country Status (10)

Country Link
EP (1) EP0463114B1 (de)
JP (1) JPH04504173A (de)
AT (1) ATE138196T1 (de)
CA (1) CA2049007A1 (de)
DE (1) DE69027025T2 (de)
FI (1) FI914160A7 (de)
IE (1) IE900786L (de)
NO (1) NO913499L (de)
PT (1) PT93337B (de)
WO (1) WO1990010871A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232722T2 (de) * 1991-08-23 2002-12-05 The Board Of Regents Of The University Of Nebraska, Lincoln Verfahren und zusammensetzungen für zelluläre reprogrammierung
WO1996010091A1 (en) * 1994-09-29 1996-04-04 Merck & Co., Inc. A high capacity screen for immunoregulants
GB9520411D0 (en) * 1995-10-06 1995-12-06 Wales College Of Medicine Method of testing
US6979547B2 (en) 1998-03-25 2005-12-27 Cornell Research Foundation, Inc. Methods for designing specific ion channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503887A (ja) * 1988-02-03 1991-08-29 エクソウマ コーポレーション 自己免疫疾患に対する抗t細胞イムノトキシンの治療的使用
JPH03503164A (ja) * 1988-02-03 1991-07-18 エクソウマ コーポレーション 抗‐パンt‐細胞イムノトキシン組成物による免疫抑制

Also Published As

Publication number Publication date
CA2049007A1 (en) 1990-09-07
NO913499D0 (no) 1991-09-05
PT93337A (pt) 1990-11-07
DE69027025D1 (de) 1996-06-20
FI914160A0 (fi) 1991-09-03
EP0463114A4 (en) 1992-01-22
EP0463114B1 (de) 1996-05-15
PT93337B (pt) 1997-01-31
IE900786L (en) 1990-09-06
EP0463114A1 (de) 1992-01-02
DE69027025T2 (de) 1996-10-24
FI914160A7 (fi) 1991-09-03
JPH04504173A (ja) 1992-07-23
WO1990010871A1 (en) 1990-09-20
NO913499L (no) 1991-09-05

Similar Documents

Publication Publication Date Title
Lies et al. Relative T‐cell specificity of lymphocytotoxins from patients with systemic lupus erythematosus
DE69333348D1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten
ES2132063T3 (es) Procedimiento para la captura y recuperacion de celulas.
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
MX167560B (es) Composicion de carbamato, procedimiento para su obtencion y aplicacion en fluidos funcionales
ATE315654T1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
ES2075050T3 (es) Peptidos que tienen actividad cooperadora de celulas t.
ES2103803T3 (es) Ensayo inmunocromatografico y metodo para utilizar el mismo.
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
ES2051744T3 (es) Hibridomas y moleculas paratopicas monoclonales de la apolipoproteina a-i.
ES2072251T3 (es) Composiciones y metodos para la sintesis y ensayo de enquefalinasa.
FR2491334B1 (de)
ES2172287T4 (es) Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa.
DE69027025D1 (de) Testverfahren für und behandlung von autoimmunkrankheiten
ES2065974T3 (es) Agente para ensayos inmunoquimicos que contiene polimeros con contenido de grupos carboxilo.
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
FR2642526B1 (fr) Utilisation de generateur de radicaux libres dans le domaine des dosages biologiques
DE3854267D1 (de) HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung.
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
DE3784468D1 (de) Testbares mehrmodus-zaehlernetz und methode zur durchfuehrung des tests.
Petitti et al. Physiologic measures in men with and without vasectomies
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor